Stifel analyst Annabel Samimy maintained a Hold rating and $24 price target on Mallinckrodt after the company released the full release of its two-part Phase 4 study of Acthar in refractory patients with persistent Rheumatoid Arthritis at EULAR, noting that both parts of the study hit all primary and secondary endpoints. In a research note to investors, Samimy says with these data that show "strong" clinical evidence in RA, she sees opportunity for Mallinckrodt to have more meaningful clinical discussions in third-party payer negotiations and greater validation with Medicare, both of which could support Acthar volumes going forward.